In this regard, a pre-clinical study demonstrated that a CCR2 antagonist shows anti-cancer effects increasing CD8+ T cells via blocking tumor-infiltrating macrophage-mediated immunosuppression, and that the anti-tumor effect was improved by combining the antagonist with low-dose sorafenib [167, 168]. The gene discussed is CCR2; the disease is neoplasm.